BBC.US Virtus LifeSci Biotech Clinical Trials ETF
- Total assets
- 31.3M
- Expense ratio
- 0.75%
- Dividend yield
- 1.49%
- 1-year return
- +43.64%
- Holdings
- 127
- Since
- 2014
Fund data as reported by the issuer, updated Nov 14, 2026. Total assets are in the fund's base currency.
What does BBC.US invest in?
- Mostly US stocks (86.2%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (93.5%)
- Top 3 holdings: 7.0% of the fund
Asset allocation
- US stocks 86.2%
- Non-US stocks 9.8%
- Cash 0.2%
Top holdings
- Kodiak Sciences Inc 2.46%
- Xencor Inc 2.42%
- First Tracks Biotherapeutics 2.15%
- Replimune Group Inc 1.92%
- Abcellera Biologics Inc 1.84%
Virtus LifeSci Biotech Clinical Trials ETF performance
Sharpe ratio 0.94- This year
- +17.87%
- 1 year
- +43.64%
- 3 years
- +40.35%
- 5 years
- +0.51%
Volatility 33.0% over 1 year and 36.6% over 3 years. High: expect large swings.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
BBC.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About Virtus LifeSci Biotech Clinical Trials ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Full fund profileVirtus LifeSci Biotech Clinical Trials ETF top holdings
17.4% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Kodiak Sciences Inc KOD.US | Healthcare | United States | 2.46% |
| Xencor Inc XNCR.US | Healthcare | United States | 2.42% |
| First Tracks Biotherapeutics TRAX.US | Healthcare | United States | 2.15% |
| Replimune Group Inc REPL.US | Healthcare | United States | 1.92% |
| Abcellera Biologics Inc ABCL.US | Healthcare | United States | 1.84% |
| Amylyx Pharmaceuticals Inc AMLX.US | Healthcare | United States | 1.65% |
| Viridian Therapeutics Inc VRDN.US | Healthcare | United States | 1.38% |
| Kymera Therapeutics Inc KYMR.US | Healthcare | United States | 1.21% |
| MBX Biosciences, Inc. Common Stock MBX.US | Healthcare | United States | 1.18% |
| LB Pharmaceuticals Inc Common Stock LBRX.US | Healthcare | United States | 1.15% |
The 10 largest of 127 holdings.
BBC.US sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
BBC.US regional exposure
- North America93.5%
- Europe Developed4.6%
- United Kingdom2.0%
- Asia Emerging0.6%
Share of the stocks in the fund.
Company size
Average market cap 1.70B- Medium cap0.9%
- Small cap22.0%
- Micro cap61.3%
Virtus LifeSci Biotech Clinical Trials ETF fund profile
- Fund name
- Virtus LifeSci Biotech Clinical Trials ETF
- Ticker
- BBC.US
- Exchange
- USA Stocks
- Issuer
- Virtus
- Index tracked
- -
- Category
- Healthcare Equity
- Domicile
- United States
- Inception date
- Dec 16, 2014
- Trading currency
- USD
- Expense ratio
- 0.75%
- Annual turnover
- 0.7%
About Virtus LifeSci Biotech Clinical Trials ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.